Table. 1 Baseline clinicopathological characteristics of the training and validation set and internal test set of surgical cohorts (n = 160)
Training and validation set Surgical cohort (N = 112) | Internal test set Surgical cohort (N = 48) | P-value | |
|---|---|---|---|
Age (years) | 66.77 ± 7.752 | 67.42 ± 7.234 | 0.612 |
Sex, n (%) | 0.216 | ||
Male | 86 (76.8%) | 41 (85.4%) | |
Female | 26 (23.2%) | 7 (14.6%) | |
Tumor size (mm) | 39.32 ± 15.15 | 31.54 ± 13.61 | 0.265 |
Location, n (%) | 0.961 | ||
Upper | 7 (6.3%) | 3 (6.3%) | |
Middle | 54 (48.2%) | 22 (45.8%) | |
Lower | 51 (45.5%) | 23 (47.9%) | |
Invasion depth | 0.896 | ||
Submucosa | 15 (13.4%) | 7 (14.6%) | |
Muscularis propria | 25 (22.3%) | 12 (25.0%) | |
Adventitia | 72 (64.3%) | 29 (60.4%) | |
Clinical stage | 0.908 | ||
Stage Ⅰ | 15 (13.4%) | 8 (16.7%) | |
Stage Ⅱ | 53 (47.3%) | 20 (41.7%) | |
Stage Ⅲ | 40 (35.7%) | 18 (37.5%) | |
Stage IV | 4 (3.6%) | 2 (4.2%) | |
Lymphovascular invasion, n (%) | 69 (61.6%) | 31 (64.6%) | 0.722 |
Perineural invasion, n (%) | 51 (45.5%) | 25 (52.1%) | 0.447 |
Differentiation grade, n (%) | 0.405 | ||
Poorly differentiated | 20 (17.9%) | 13 (27.1%) | |
Moderately differentiated | 87 (77.7%) | 34 (70.8%) | |
Well differentiated | 5 (4.5%) | 1 (2.1%) | |
Tumor budding* | 0.405 | ||
Low-grade budding | 5 (4.5%) | 1 (2.1%) | |
Intermediate-grade budding | 87 (77.7%) | 34 (70.8%) | |
High-grade budding | 20 (17.9%) | 13 (27.1%) | |
Lymph node metastasis (+), n (%) | 52 (46.4%) | 20 (41.6%) | 0.579 |
Number of dissected lymph nodes, n | 29.98 ± 11.21 | 27.65 ± 10.50 | 0.426 |
